AstraZeneca India Unit Puts Off Delisting From Local Stock Exchanges
This article was originally published in PharmAsia News
AstraZeneca Pharma India decided to reschedule its plan to remove itself from India stock exchanges on advice of advisers who wanted clarifications and explanations.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.